FDA Grants a oeOrphan Druga Designation for Genervona s Breakthrough Multi-Target ALS Bio-Drug GM604

Genervon expects to present the analysis of the unblinded results of ALS, PD and Ischemic Stroke trials by the Fall )--Genervon Biopharmaceuticals announced today that the U.S. Food and Drug Administration has granted an "orphan drug" designation to Genervon's GM604 bio-drug for the treatment of Amyotrophic Lateral Sclerosis .

http://ift.tt/1eTPDSj